- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 15:06 | Freenome, Inc.: FDA Grants Breakthrough Device Designation to Freenome's Blood-Based SimpleScreen Lung Cancer Screening Test | 75 | GlobeNewswire (Europe) | BRISBANE, Calif., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Freenome, Inc. (Nasdaq: FRNM), an early cancer detection company developing blood-based screening tests, today announced that the U.S. Food and... ► Artikel lesen | |
| 24.07. | Freenome, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 20.07. | NSE - Freenome, Inc. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | 2 | SEC Filings | ||
| 20.07. | Freenome Holdings, Inc. - 15-15D, Suspension of duty to report | 2 | SEC Filings | ||
| 20.07. | Freenome, Inc. - 8-A12B, Registration of securities | 1 | SEC Filings | ||
| 20.07. | Krebsdiagnostik-Spezialist Freenome geht via SPAC an die Nasdaq | - | Investing.com Deutsch | ||
| FREENOME Aktie jetzt für 0€ handeln | |||||
| 20.07. | Freenome, Inc.: Freenome Debuts as a Publicly Traded Company Focused on Blood-Based Early Cancer Detection | 338 | GlobeNewswire (Europe) | - Freenome common stock expected to begin trading on the Nasdaq Capital Market under the ticker symbol "FRNM" on July 21, 2026 - - Gross proceeds to Freenome totaled more than $300 million through... ► Artikel lesen | |
| 13.07. | Freenome colorectal cancer test data improve on earlier results | 1 | BioPharma Dive | ||
| 11.06. | Freenome Holdings, Inc. - S-4/A, Registration of securities, business combinations | - | SEC Filings | ||
| 01.06. | Freenome Holdings, Inc. - S-4/A, Registration of securities, business combinations | 2 | SEC Filings | ||
| 28.04. | Freenome Holdings, Inc. - S-4, Registration of securities, business combinations | - | SEC Filings | ||
| 05.12.25 | Freenome Holdings, Inc.: Freenome and Perceptive Capital Solutions Corp Announce Business Combination Agreement to Create a Publicly Listed Company Transforming Blood-Based Multi-Cancer Detection through an AI/ML-Enabled Multiomics Platform | 713 | PR Newswire | - Leading institutional investors commit $240 million through private investment in public equity (PIPE) led by Perceptive Advisors and RA Capital -
- Freenome... ► Artikel lesen |
12 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 37,040 | -0,09 % | Ihre wichtigsten Termine: Frische Zahlen von Ebay, Eli Lill, Allstate, Infineon, Novo Nordisk, Walt Disney | Gut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Untermehmenstermine 06:45 Uhr, Deutschland: Basler... ► Artikel lesen | |
| BIOVIE | 1,740 | +37,01 % | New to The Street Show 766 Broadcasts Tonight at 6:30 PM ET on Bloomberg Television, Featuring BioVie's Bezisterim Parkinson's Disease Clinical Results | Sponsored Programming Also Broadcasts Across Bloomberg Television in Latin America and MENA, Expanding the Global Reach of New to The Street's Featured Companies NEW YORK CITY, NY / ACCESS Newswire... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 134,59 | -0,08 % | Apogee Therapeutics: Apogee Reports Second Quarter 2026 Financial Results and Recent Corporate and Pipeline Updates | AbbVie to acquire Apogee for $135.11 per share in cash for total equity value of approximately $10.9 billion, positioning differentiated immunology portfolio to reach more patients worldwide Positive... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 377,30 | +1,79 % | Praxis Precision Medicines, Inc. - 10-Q, Quarterly Report | ||
| ERASCA | 18,960 | +3,55 % | Erasca, Inc.: Erasca Reports Second Quarter 2026 Business Updates and Financial Results | Updated ERAS-0015 data in U.S. trial highlighted compelling monotherapy efficacy in 2L+ KRAS G12X PDAC and continued favorable tolerability, as well as further advancement of panitumumab CRC combination... ► Artikel lesen | |
| IMMUNOME | 27,045 | +3,03 % | Immunome GAAP EPS of -$0.65 misses by $0.13 | ||
| MOONLAKE IMMUNOTHERAPEUTICS | 17,100 | +3,07 % | MoonLake Immunotherapeutics AG: MoonLake Announces Positive Topline Results from the Phase 3 IZAR-1 Trial of Sonelokimab in Psoriatic Arthritis Demonstrating Significant Improvements Across all Clinical Endpoints, and Reports Second Quarter 2026 Financial | Phase 3 IZAR-1 trial in bio-naïve patients met all clinical endpoints at Week 16 for 60 mg sonelokimabThe primary endpoint of ACR50 was met with a high response of 42.1% for sonelokimab's 60 mg with... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 15,290 | +1,16 % | H.C. Wainwright reiterates Neutral stock rating on Summit Therapeutics | ||
| ENLIVEN THERAPEUTICS | 59,05 | +0,45 % | Guggenheim lowers Enliven Therapeutics stock price target to $78 | ||
| TANGO THERAPEUTICS | 26,430 | +0,34 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights | Company continues to prepare for late-stage clinical advancement of vopimetostat in combination with daraxonrasib for pancreatic cancer following positive Phase 1/2 data Phase 1/2 data from combination... ► Artikel lesen | |
| EVOTEC | 3,850 | +3,89 % | EQS-News: Evotec SE: Evotec und Odyssey Therapeutics starten KI-gestützte F&E-Kooperation in Autoimmun- und Entzündungserkrankungen | EQS-News: Evotec SE
/ Schlagwort(e): Sonstiges
Evotec und Odyssey Therapeutics starten KI-gestützte F&E-Kooperation in Autoimmun- und Entzündungserkrankungen
06.08.2026... ► Artikel lesen | |
| ABSCI | 9,395 | -0,16 % | Absci Corporation: Absci Reports Business Updates and Second Quarter 2026 Financial and Operating Results | Announced positive interim Phase 1 data from the HEADLINE trial of ABS-201 Completed $100 million underwritten offering, including $40 million strategic investment from Eli Lilly & Company Cash, cash... ► Artikel lesen | |
| SIONNA THERAPEUTICS | 6,070 | +19,02 % | Sionna Therapeutics, Inc.: Sionna Therapeutics Reports Topline Data from Two Development Programs in Cystic Fibrosis and Provides Corporate Update | SION-719 Phase 2a proof-of-concept trial did not achieve key activity endpoint of sweat chloride reduction when added to standard of care; Company is not advancing SION-719 as an add-on to standard... ► Artikel lesen | |
| DYNE THERAPEUTICS | 26,620 | -0,34 % | PetAg expands Tractor Supply distribution of supplements, life-stage nutrition: The company's Dyne Soft Chews and Esbilac ... | ||
| COGENT BIOSCIENCES | 38,240 | -1,19 % | Cogent Biosciences, Inc. - 10-Q, Quarterly Report |
FREENOME INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,470 (-3,92 %) liegt der Kurs bei 11,530 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu FREENOME INC finden Sie auf Wallstreet Online.